Literature DB >> 23656495

Long double-stranded multiplex siRNAs for dual genes silencing.

Wei Peng1, Jianxin Chen, Yinchao Qin, Zhenjun Yang, York Yuanyuan Zhu.   

Abstract

Simultaneous suppression of multiple oncogenes is an attractive strategy to treat cancers. Herein we present a series of long double-stranded multiplex small interfering RNAs (multi-siRNAs) that is suitable for dual genes silencing through a sequence-specific RNA interference process without inducing significant immune responses. A gap feature structurally designed in either of the nucleotide strands of the multi-siRNAs was proved to be essential toward silencing target genes and avoiding immune responses. Furthermore, the silencing effect of multi-siRNAs against SURVIVIN and BCL-2 genes was shown to be effective and resulted in up-regulation of caspase-3 related apoptosis and, in turn, inhibition of bladder cancer cell proliferation. Our observation suggested that the rationally designed multi-siRNAs would have great potential for therapeutic siRNA design.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23656495      PMCID: PMC3723238          DOI: 10.1089/nat.2013.0416

Source DB:  PubMed          Journal:  Nucleic Acid Ther        ISSN: 2159-3337            Impact factor:   5.486


  21 in total

1.  RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals.

Authors:  P D Zamore; T Tuschl; P A Sharp; D P Bartel
Journal:  Cell       Date:  2000-03-31       Impact factor: 41.582

2.  A comprehensive view of regulation of gene expression by double-stranded RNA-mediated cell signaling.

Authors:  G Geiss; G Jin; J Guo; R Bumgarner; M G Katze; G C Sen
Journal:  J Biol Chem       Date:  2001-08-10       Impact factor: 5.157

3.  Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells.

Authors:  Frank Czauderna; Melanie Fechtner; Sibylle Dames; Hüseyin Aygün; Anke Klippel; Gijsbertus J Pronk; Klaus Giese; Jörg Kaufmann
Journal:  Nucleic Acids Res       Date:  2003-06-01       Impact factor: 16.971

4.  Argonaute2 is the catalytic engine of mammalian RNAi.

Authors:  Jidong Liu; Michelle A Carmell; Fabiola V Rivas; Carolyn G Marsden; J Michael Thomson; Ji-Joon Song; Scott M Hammond; Leemor Joshua-Tor; Gregory J Hannon
Journal:  Science       Date:  2004-07-29       Impact factor: 47.728

5.  Induction of apoptosis by survivin silencing through siRNA delivery in a human breast cancer cell line.

Authors:  Hamidreza Montazeri Aliabadi; Breanne Landry; Parvin Mahdipoor; Hasan Uludağ
Journal:  Mol Pharm       Date:  2011-08-23       Impact factor: 4.939

6.  Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation.

Authors:  Tim A Rand; Sean Petersen; Fenghe Du; Xiaodong Wang
Journal:  Cell       Date:  2005-11-03       Impact factor: 41.582

Review 7.  Emerging roles of caspase-3 in apoptosis.

Authors:  A G Porter; R U Jänicke
Journal:  Cell Death Differ       Date:  1999-02       Impact factor: 15.828

8.  Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells.

Authors:  Javier A Menendez; Luciano Vellon; Inderjit Mehmi; Bharvi P Oza; Santiago Ropero; Ramon Colomer; Ruth Lupu
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-02       Impact factor: 11.205

Review 9.  Why target apoptosis in cancer treatment?

Authors:  Shailaja Kasibhatla; Ben Tseng
Journal:  Mol Cancer Ther       Date:  2003-06       Impact factor: 6.261

10.  Characterization of the 2'-5'-oligoadenylate synthetase ubiquitin-like family.

Authors:  Signe Eskildsen; Just Justesen; Mikkel Heide Schierup; Rune Hartmann
Journal:  Nucleic Acids Res       Date:  2003-06-15       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.